MMAVD was associated with more pronounced cardiac reverse remodeling after TAVR, while survival remained comparable to isolated severe AS.The study, published in The American Journal of Cardiology, evaluated outcomes after TAVR using a propensity-matched cohort analysis.

A propensity-matched cohort included 73 MMAVD and 264 isolated AS patients who underwent TAVR between 2019 and 2024. Baseline disease severity differed across groups, and post-procedural outcomes were assessed after valve replacement.

MMAVD showed greater structural impairment at baseline, with a larger left ventricular end-diastolic diameter (LVEDD) of 56.07±9.04 mm versus 50.68±7.70 mm and a higher left ventricular mass index (LVMI) of 163.68±50.17 g/m² versus 151.59±44.38 g/m². Following TAVR, MMAVD demonstrated larger LVEDD improvement, with a reduction of −7.18±9.75 mm versus −2.52±7.64 mm. Left ventricular ejection fraction (LVEF) recovery was similar between groups (5.47±13.98% versus 6.88±15.20%). Survival did not differ (log-rank p=0.370).

However, MMAVD had higher one-year HF rehospitalization 5.97% versus 0.96%, indicating persistent clinical vulnerability despite remodeling benefits.